PAVmed子公司Lucid Diagnostics在退伍军人事务部合同中飙升

2026-01-21 21:47

Lucid Diagnostics (LUCD), a subsidiary of healthcare equipment maker PAVmed (PAVM), added ~10% in the premarket on Wednesday after the company announced that the U.S. Department of Veterans Affairs has awarded it a contract to supply its EsoGuard Esophageal DNA Test.
The contract issued under the VA Federal Supply Schedule allows the company to price EsoGuard at a level matching the payment rate offered by Medicare, Lucid (LUCD) said in a press release.
It also allows LUCD to supply EsoGuard through a single, national VA procurement framework and expand its presence in the largest integrated healthcare system in the U.S.
"We are proud to partner with the U.S. Department of Veterans Affairs to expand access to EsoGuard for our nation's veterans," Chief Operating Officer of Lucid, Shaun O'Neil, remarked.

More on Lucid Diagnostics, PAVmed